ReviewJournal of clinical and translational hepatology2021
Cytomegalovirus Hepatitis in Immunocompetent and Immunocompromised Hosts.
Review in Journal of clinical and translational hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- A Predictive Model for Cytomegalovirus Infection Using Routine Hematological and Biochemical Parameters:Saudi medical journal · 2026Article
- Higher prevalence of cytomegalovirus and Epstein-Barr virus in acute-on-chronic liver failure.JHEP reports : innovation in hepatology · 2026Article
- HCMV infection disrupts barrier functions and promotes epithelial-mesenchymal transition in a cholangiocyte organoid model.Nature communications · 2026Article
- When serology misleads: cross-reactivity in acute hepatitis.Archives of virology · 2025Review
- Non hepatotropic virus induced hepatitis - rising importance in a changing world.World journal of virology · 2025Review
- Review
- Universal STING Pathway-Activating Complexes Counteract Viral Immune Evasion and Boost Antiviral Responses.ACS nano · 2025Article
- Liver diseases: epidemiology, causes, trends and predictions.Signal transduction and targeted therapy · 2025Review
- CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patients.Cancer immunology, immunotherapy : CII · 2025Article
- Cytomegalovirus Gastritis Mimicking a Gastroesophageal Junction Malignancy in an AIDS Patient: A Case Report.Cureus · 2025Article
- Immune surveillance of cytomegalovirus in tissues.Cellular & molecular immunology · 2024Review
- Human cytomegalovirus microRNAs: strategies for immune evasion and viral latency.Archives of virology · 2024Review
- Granulomatous liver diseases.Hepatology communications · 2024Review
- Exploring Peripheral Blood-Derived Extracellular Vesicles as Biomarkers: Implications for Chronic Chagas Disease with Viral Infection or Transplantation.Microorganisms · 2024Article
- The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study.Frontiers in pediatrics · 2024Article
- Mouse Models for Human Herpesviruses.Pathogens (Basel, Switzerland) · 2023Review
- A rare case of cytomegalovirus hepatitis mimicking malignancy in an immunocompetent adult.Radiology case reports · 2023Article
- Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases.Nanoscale horizons · 2022Review
- Non-hepatotropic viral hepatitis and its causative pathogens: The ongoing need for monitoring in children with severe acute hepatitis of unknown etiology.Pediatric investigation · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human cytomegalovirus (HCMV) infection is common and affects between 40-100% of the worldwide population. However, the majority of cases are asymptomatic and when severe disease occurs, it is usually restricted to immunocompromised patients. Liver involvement by HCMV differs significantly, accordingly to the immune status of the host. In immunocompromised patients, particularly liver transplant patients, it often causes clinically significant hepatitis. On the other hand, in immunocompetent patients, HCMV hepatitis requiring hospitalization is extremely rare. This review aims to appraise studies regarding the pathophysiology of HCMV hepatitis, including mechanisms of latency and reactivation and its contribution to disease development, clinical presentation, diagnostic modalities and treatment, with a focus on comparing different aspects between immunocompromised and immunocompetent hosts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.